Project Grant R21AI202655
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $262K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denver, CO 80206, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded National Jewish Health $470,219 on February 5, 2026, through the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of resident memory T cells in chronic lung disease viral infections. The research examines how lung-resident memory T cells (TRM cells) regulate susceptibility to recurrent influenza virus infections in chronic obstructive pulmonary disease (COPD) patients. The project focuses on...
- The National Institute of Allergy and Infectious Diseases awarded National Jewish Health $164,350 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate glucose and glutamine transport as novel targets in cystic fibrosis immune responses. The research examines solute carrier proteins SLC2A4RG and SLC38A9, which show significant expression changes in CD3+ T cells following triple combination CFTR modulator therapy...
- The National Institute of Allergy and Infectious Diseases awarded New York University $755,801 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the regulation of CD4+ and CD8+ T cell function by CLNS1A. The research examines the mechanisms controlling T lymphocyte function in immunity to infection and cancer, as well as in autoimmune and allergic diseases. The project uses forward genetics screens in animal models of brain and...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $622,850 on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the heterogeneous functions, antigen specificities, and lipid antigen restrictions of human CD4-/CD8- double-negative T cells (DN T cells). The research examines how CD1-restricted DN T cell populations respond to CD1-presented self-lipid antigens and...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $184,000 on April 1, 2026, to investigate how CD14 regulates NLRP3 inflammasome signaling pathways in renal tubule epithelial cells during ischemia-reperfusion injury. The work is supported under the Allergy and Infectious Diseases Research program (CFDA 93.855), a project grant assistance type. The research evaluates whether CD14 engages toll-like receptors (TLR2 or TLR4) to trigger NLRP3 signaling in...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $552,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct functional characterization of dendritic cell heterogeneity for T cell-inducing immunotherapies. The research addresses vaccine development for intracellular pathogens including HIV/AIDS and malaria by investigating the distinct roles of type 1 and type 2 conventional dendritic cells in...
- The National Institute of Allergy and Infectious Diseases awarded Beckman Research Institute of the City of Hope $489,500 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify and characterize novel molecular pathways regulating inflammatory responses, with particular focus on non-canonical mir-146a biogenesis and its role in immune homeostasis. The research will characterize post-transcriptional mechanisms controlling mir-146a production,...
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...